Children , adolescents , and young adults ages 0 to 29 years with newly diagnosed AML were enrolled onto Childrens Oncology Group trial AAML0531 and then were randomly assigned to either standard five-course chemotherapy alone or to the same chemotherapy with two doses of GO ( 3 mg/m2/dose ) administered once in induction course 1 and once in intensification course 2 ( two of three ) .